EHA 2026 | Cell Therapy Hub

Title	Author List	Presentation information
Axicabtagene Ciloleucel as Second-line Treatment in Patients with Late-relapsed LBCL: Interim Analysis of the LATE-R Clinical Trial from the Spanish Lymphoma Group GELTAMO	Mariana Bastos-Oreiro, Armando L+	Poster Session 1: Friday, June 12 (18:45
Axicabtagene Ciloleucel for the Treatment of R/R DLBCL in Brazil: The Impact of CAR T-cell Therapy Wait Time and Treatment Sequencing	Jo+	Abstract Code: PB3720
Biologic Correlates of Long	Sabina Adhikary, Kelly Speth, Colleen Schweitzer, Rhine Shen, Ioana Kloos, Marie Jos+	Poster Session 2: Saturday, June 13 (18:45
CAR T Cell Therapy in Clinical Routine: Quantification of Real-World Hospital Resource Use Across CAR T Care Pathway in Germany	Katja Hesse, Isabell Kaufhold, Markus Finzsch, Florian Kron	Poster Session 1: Friday, June 12 (18:45
Clinical and Economic Outcomes by Risk Group Among First-Line Patients with LBCL in the United States (US)-SEER-Medicare Data Analysis	Yi Lin, Liana Nikolaenko, Elyse Swallow, Madhu Palivela, Jinlin Song, Markqayne Ray, Sakshi Sethi, David Cobley, Matthew…	Abstract Code: PB3775
Cost-Effectiveness Analysis of Brexucabtagene Autoleucel in Adults with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukaemia in Singapore	Esther Chan, Nurul A Abdul Halim, Tza Kai Diong, Emma New, Briana Tan, Francesca L.W.I. Lim	Poster Session 2: Saturday, June 13 (18:45
Cost-Effectiveness of Axicabtagene Ciloleucel for Treating Taiwanese Patients with R/R DLBCL and High-Grade B-cell Lymphoma After First-Line Treatment	Bor-Sheng Ko, Wen-Wen Yang, Yu-Chiao Wang, Diong Tza-Kai, Kuan-Der Lee, Raoh-Fang Pwu	Poster Session 2: Saturday, June 13 (18:45
Cost-Effectiveness of Axicabtagene Ciloleucel in Taiwanese Patients with R/R DLBCL and Primary Mediastinal B-Cell Lymphoma After Two Lines of Systemic Therapy	Kuan-Der Lee, Yu-Chiao Wang, Wen-Wen Yang, Diong Tza-Kai, Bor-Sheng Ko, Raoh-Fang Pwu	Poster Session 1: Friday, June 12 (18:45
Exploring Global Variation in CAR T-Cell Therapy Practice Patterns for LBCL: Quantitative Research Findings	Samuel Yamshon, Gloria Ines Iacoboni Garcia-Calvo, David Qualls, Ajay Major, Lizamarie Bachier-Rodriguez, Anna Maria Sur…	Abstract Code: PB3712
Follow-Up Time	Michael Leisch, Thomas Melchardt, Guido Ghilardi, Caroline Arber, Ulrich J+	Poster Session 2: Saturday, June 13 (18:45
International Expert Consensus on Real-World CAR T-Cell Eligibility in LBCLs: An e-Delphi Study	Catherine Thieblemont, Isabelle Fleury, Mazyar Shadman, Tobias A.W. Holderried, Graham Collins	Poster Session 1: Friday, June 12 (18:45
Real-World Treatment Patterns and Survival Outcomes in Patients With Newly Diagnosed High-Risk LBCL	Ran Reshef, Javier Munoz, Babatunde Adedokun, Qian Huang, Hil Hsu, Nan Liu, Madhu Palivela, Zhen-Huan Hu, Liana Nikolaen…	Poster Session 1: Friday, June 12 (18:45

CAR, chimeric antigen receptor; DLBCL, diffuse large B-cell lymphoma; LBCL, large B-cell lymphoma; MCL, mantle cell lymphoma; (R/R) DLBCL, (relapse/refractory) diffuse large B-cell lymphoma.

DELIVERING OUTCOMES, NOT JUST CELLS:

WHY SPEED AND RELIABILITY MATTER FOR CAR T PATIENTS

Saturday, 13 June 2026 | 10:00–11:30 CEST

A2-3 Hall, Stockholmsmässan, Massvagen 1, 125 30 Alvsjö, Sweden

This non-promotional symposium is organised and funded by Gilead and Kite through Kite Pharma, Inc. The safety and efficacy of investigational agents have not been established, and they have not received marketing authorisation in this setting. There is no guarantee that investigational agents and/or uses will receive Health Authority approval and/or become commercially available.